<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2025-2401</article-id><article-id custom-type="edn" pub-id-type="custom">KAQGPZ</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-2537</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Оценка безопасности достижения рекомендуемых целевых уровней артериального давления у пациентов пожилого и старческого возраста: протокол рандомизированного открытого проспективного прагматического исследования ПОРОГ (БезоПасность дОстижения РекОмендуемых целевых уровней артериального давления в Гериатрической практике)</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the safety of achieving recommended blood pressure targets in elderly patients: protocol of a randomized, open‑label, prospective, pragmatic study THReshOld (Treatment of Hypertension to Recommended blood pressure in Old patients with hypertension)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8505-1848</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиляревский</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyarevsky</surname><given-names>Sergey R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиляревский Сергей Руджерович — доктор медицинских наук, профессор, ведущий научный сотрудник, </p><p>Москва.</p><p>RESEARCH ID: AAN-4179–2021</p></bio><bio xml:lang="en"><p>Sergey R. Gilyarevsky, MD, PhD, DSc, Professor, Cardiology Center, </p><p>Moscow.</p></bio><email xlink:type="simple">sgilarevsky@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3981-4031</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щедрина</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchedrina</surname><given-names>Anna Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щедрина Анна Юрьевна — кандидат медицинских наук, заведующая кардиологическим отделением, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Anna Yu. Shchedrina, MD, PhD, Head, Department of Cardiology,</p><p>Moscow.</p></bio><email xlink:type="simple">ashedrina@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0048-268X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ерусланова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Eruslanova</surname><given-names>Ksenia A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ерусланова Ксения Алексеевна — кандидат медицинских наук, заведующая лабораторией сердечно-сосудистого старения, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Ksenia A. Eruslanova, MD, PhD, Head, Laboratory of Cardiovascular Aging,</p><p>Moscow.</p></bio><email xlink:type="simple">eruslanova_ka@rgnkc.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4778-7755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кожевникова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozhevnikova</surname><given-names>Maria V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кожевникова Мария Владимировна — кандидат медицинских наук, профессор кафедры,  </p><p>Москва.</p></bio><bio xml:lang="en"><p>Maria V. Kozhevnikova, MD, PhD, Professor of the Department of Internal Diseases № 1,</p><p>Moscow.</p></bio><email xlink:type="simple">kozhevnikova_m_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1695-9107</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лузина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Luzina</surname><given-names>Aleksandra V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лузина Александра Вячеславовна — кандидат медицинских наук, научный сотрудник лаборатории сердечно-сосудистого старения,</p><p>Москва.</p></bio><bio xml:lang="en"><p>Aleksandra V. Luzina, Md, PhD, Laboratory of Vascular Ageing,</p><p>Moscow.</p></bio><email xlink:type="simple">alexalav@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5748-1536</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Готина</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Gotina</surname><given-names>Alisa D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Готина Алиса Дмитриевна — младший научный сотрудник лаборатории сердечно-сосудистого старения, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Alisa D. Gotina, Junior Researcher, Laboratory of Cardiovascular Aging,</p><p>Moscow.</p></bio><email xlink:type="simple">gotina_ad@rgnkc.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2596-192X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Железных</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheleznykh</surname><given-names>Elena A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Железных Елена Анатольевна — кандидат медицинских наук, доцент кафедры, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Elena A. Zheleznykh, MD, PhD, Associate Professor of the Department of Internal Diseases № 1,</p><p>Moscow.</p></bio><email xlink:type="simple">zheleznykh_e_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4027-3727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Закиев</surname><given-names>В. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakiev</surname><given-names>Vadim D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Закиев Вадим Дмитриевич — младший научный сотрудник лаборатории клинической фармакологии и фармакотерапии, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Vadim D. Zakiev, Junior Researcher,</p><p>Moscow.</p></bio><email xlink:type="simple">zakiev739@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1628-5093</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котовская</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotovskaya</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котовская Юлия Викторовна — доктор медицинских наук, профессор, заместитель директора по научной работе, </p><p>Москва.</p></bio><bio xml:lang="en"><p>Yulia V. Kotovskaya, MD, PhD, DSc, Professor, Deputy Director,</p><p>Moscow.</p></bio><email xlink:type="simple">kotovskaya_yv@rgnkc.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3014-6129</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беленков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беленков Юрий Никитич — доктор медицинских наук, профессор, академик РАН, заведующий кафедрой,  </p><p>Москва.</p></bio><bio xml:lang="en"><p>Yuri N. Belenkov, MD, PhD, DSc, Professor, Academician RAN, Head, Department of the Internal Diseases № 1, </p><p>Moscow.</p></bio><email xlink:type="simple">belenkov_yu_n@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5451-2915</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkacheva</surname><given-names>Olga N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ткачева Ольга Николаевна — директор, доктор медицинских наук, профессор, член-корреспондент РАН, главный внештатный гериатр Минздрава России,</p><p>Москва.</p></bio><bio xml:lang="en"><p>Olga N. Tkacheva, Director of Institution, MD, PhD, DSc, Professor, Correspondent- member RAN,  Chief Freelance Geriatrician of the Russian Ministry of Health,</p><p>Moscow.</p></bio><email xlink:type="simple">tkacheva@rgnkc.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Обособленное структурное подразделение «Российский геронтологический научно-клинический центр» Федерального государственного автономного образовательного учреждения высшего образования  «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Gerontological Scientific and Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Обособленное структурное подразделение «Российский геронтологический научно-клинический центр» Федерального государственного автономного образовательного учреждения высшего образования  «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова»  &#13;
Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Gerontological Scientific and Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кафедра госпитальной терапии № 1 Института клинической медицины им. Н. В. Склифосовского Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации  (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>05</month><year>2025</year></pub-date><volume>31</volume><issue>1</issue><fpage>47</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гиляревский С.Р., Щедрина А.Ю., Ерусланова К.А., Кожевникова М.В., Лузина А.В., Готина А.Д., Железных Е.А., Закиев В.Д., Котовская Ю.В., Беленков Ю.Н., Ткачева О.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гиляревский С.Р., Щедрина А.Ю., Ерусланова К.А., Кожевникова М.В., Лузина А.В., Готина А.Д., Железных Е.А., Закиев В.Д., Котовская Ю.В., Беленков Ю.Н., Ткачева О.Н.</copyright-holder><copyright-holder xml:lang="en">Gilyarevsky S.R., Shchedrina A.Y., Eruslanova K.A., Kozhevnikova M.V., Luzina A.V., Gotina A.D., Zheleznykh E.A., Zakiev V.D., Kotovskaya Y.V., Belenkov Y.N., Tkacheva O.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/2537">https://htn.almazovcentre.ru/jour/article/view/2537</self-uri><abstract><p>Основная цель исследования состоит в проверке гипотезы о том, что достижение более низких рекомендуемых целевых уровней (НЦУ) артериального давления (АД) у пациентов с артериальной гипертензией (АГ) пожилого и старческого возраста будет не менее безопасно по сравнению с достижением более высоких рекомендуемых целевых уровней (ВЦУ) АД у пациентов АГ пожилого и старческого возраста, которое будет оцениваться по данным домашнего измерения АД и системы удаленного мониторинга эффективности и безопасности антигипертензивной терапии. Материалы и методы. В исследование предполагается включить 60 пациентов в возрасте 65 лет и старше, которые будут рандомизированно распределены в группу НЦУ или ВЦУ АД с достижением рекомендуемых целевых уровней САД (по данным домашнего измерения АД) менее 125 или менее 135 мм рт. ст. Эффективность вмешательства будет оцениваться по следующим показателям: частота развития эпизодов артериальной гипотензии (САД менее 100 мм рт. ст.) с клиническими проявлениями или в их отсутствие; частота развития обмороков или предобмороков; частота падений в целом и травматических падений; оценка по шкале переносимости АГТ (шкала, разработанная Duarte-Silva D. и соавт., 2014); оценка качества жизни с помощью болезнь-специфичной шкалы Quality of Life Questionnaire on Hypertension; продолжительность периода, в течение которого САД будет находиться в терапевтическом диапазоне в процентах от общей продолжительности наблюдения. Кроме того, предполагается оценивать показатели старческой астении и показатели когнитивных функций. Анализ полученных данных будет выполняться с помощью метода Win Ratio в иерархическом порядке. Предполагаемые результаты. В ходе выполнения исследования будут получены данные о возможностях дистанционного мониторинга с подбором АГТ у лиц в возрасте 65 лет и старше с целью достижения целевых уровней АД, а также информация о переносимости АГТ при ее подборе с целью достижения более низких рекомендуемых уровней АД у таких пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Objective — the main objective of the study is to test the hypothesis that achieving lower recommended target levels (LRT) of blood pressure (BP) in elderly and senile patients with arterial hypertension (HTN) will be no less safe than achieving higher recommended target levels (HRT) of BP in elderly and senile patients with HTN, which will be assessed using home BP measurement data and a remote monitoring system for the effectiveness and safety of antihypertensive therapy. Design and methods. The study is expected to include 60 patients aged 65 years and older, who will be randomly assigned to the LRT or HRT BP group with the achievement of recommended target levels of SBP (according to home BP measurement data) of less than 125 or less than 135 mmHg. The effectiveness of the intervention will be assessed by the following indicators: the frequency of episodes of arterial hypotension (SBP less than 100 mmHg) with or without clinical manifestations; frequency of fainting or pre-syncope; frequency of falls in general and traumatic falls; assessment using the AHT tolerability scale (scale developed by Duarte-Silva D. et al., 2014); assessment of quality of life using the disease- specific Quality of Life Questionnaire on Hypertension scale; duration of the period during which SBP will be in the therapeutic range as a percentage of the total observation period. In addition, it is supposed to assess the indicators of frailty and indicators of cognitive functions. The analysis of the obtained data will be performed using the Win Ratio method in a hierarchical order. Expected results. The study will provide data on the possibilities of remote monitoring with the selection of AHT in individuals aged 65 years and older in order to achieve target BP levels, as well as information on the tolerability of AHT when it is selected in order to achieve lower recommended BP levels in such patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>артериальное давление</kwd><kwd>дистанционный мониторинг артериального давления</kwd><kwd>гериатрическая практика</kwd><kwd>пациенты пожилого возраста</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>blood pressure</kwd><kwd>remote blood pressure monitoring</kwd><kwd>geriatric practice</kwd><kwd>elderly patients</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Muntner P, Miles MA, Jaeger BC, Hannon IL, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971–1980. https://doi.org/10.1161/HYPERTENSIONAHA.122.19222</mixed-citation><mixed-citation xml:lang="en">Muntner P, Miles MA, Jaeger BC, Hannon IL, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971–1980. https://doi.org/10.1161/HYPERTENSIONAHA.122.19222</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–1200. https://doi.org/10.1001/jama.2020.14545</mixed-citation><mixed-citation xml:lang="en">Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–1200. https://doi.org/10.1001/jama.2020.14545</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sakhuja S, Colvin CL, Akinyelure OP, Jaeger BC, Foti K, Oparil S, et al. Reasons for uncontrolled blood pressure among US adults: data from the US National Health and Nutrition Examination Survey. Hypertension. 2021;78:1567–1576. https://doi.org/10.1161/HYPERTENSIONAHA.121.17590</mixed-citation><mixed-citation xml:lang="en">Sakhuja S, Colvin CL, Akinyelure OP, Jaeger BC, Foti K, Oparil S, et al. Reasons for uncontrolled blood pressure among US adults: data from the US National Health and Nutrition Examination Survey. Hypertension. 2021;78:1567–1576. https://doi.org/10.1161/HYPERTENSIONAHA.121.17590</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. STEP Study Group. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–1279. https://doi.org/10.1056/NEJMoa2111437</mixed-citation><mixed-citation xml:lang="en">Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. STEP Study Group. Trial of intensive blood- pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–1279. https://doi.org/10.1056/NEJMoa2111437</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Carey RM, Muntner Р, Bosworth H, Whelton PK. Prevention and control of hypertension. J Am Coll Cardiol. 2018;72:1278–1293. https://doi.org/10.1016/j.jacc.2018.07.008</mixed-citation><mixed-citation xml:lang="en">Carey RM, Muntner Р, Bosworth H, Whelton PK. Prevention and control of hypertension. J Am Coll Cardiol. 2018;72:1278–1293. https://doi.org/10.1016/j.jacc.2018.07.008</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74:1728–1731. https://doi.org/10.1016/j.jacc.2019.08.014</mixed-citation><mixed-citation xml:lang="en">Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74:1728–1731. https://doi.org/10.1016/j.jacc.2019.08.014</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berlowitz DR. Clinical inertia and the 2017 ACA/AHA guideline. J Clin Hypertens. 2018;20:1392–1394. https://doi.org/10.1111/jch.13373</mixed-citation><mixed-citation xml:lang="en">Berlowitz DR. Clinical inertia and the 2017 ACA/AHA guideline. J Clin Hypertens. 2018;20:1392–1394. https://doi.org/10.1111/jch.13373</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chiu N, Chiu L, Aggarwal R, Raber I, Bhatt DL, Mukamal KJ. Trends in blood pressure treatment intensification in older adults with hypertension in the United States, 2008 to 2018. Hypertension. 2022;80:553–562. https://doi.org/10.1161/hypertensionaha.122.19882</mixed-citation><mixed-citation xml:lang="en">Chiu N, Chiu L, Aggarwal R, Raber I, Bhatt DL, Mukamal KJ. Trends in blood pressure treatment intensification in older adults with hypertension in the United States, 2008 to 2018. Hypertension. 2022;80:553–562. https://doi.org/10.1161/hypertensionaha.122.19882</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &gt;/=75 years: a randomized clinical trial. J Am Med Assoc. 2016;315:2673–2682. https://doi.org/10.1001/jama.2016.7050</mixed-citation><mixed-citation xml:lang="en">Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &gt;/=75 years: a randomized clinical trial. J Am Med Assoc. 2016;315:2673–2682. https://doi.org/10.1001/jama.2016.7050</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, et al. Evidence for age bias contributing to therapeutic inertia in blood pressure management: a secondary analysis of SPRINT. Hypertension. 2023;80(7):1484–1493. https://doi.org/10.1161/HYPERTENSIONAHA.123.21323</mixed-citation><mixed-citation xml:lang="en">Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, et al. Evidence for age bias contributing to therapeutic inertia in blood pressure management: a secondary analysis of SPRINT. Hypertension. 2023;80(7):1484–1493. https://doi.org/10.1161/HYPERTENSIONAHA.123.21323</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Alhawassi TM, Krass I, Pont LG. Prevalence, prescribing and barriers to effective management of hypertension in older populations: a narrative review. J Pharm Policy Pract. 2015;8:24. https://doi.org/10.1186/s40545-015-0042-6</mixed-citation><mixed-citation xml:lang="en">Alhawassi TM, Krass I, Pont LG. Prevalence, prescribing and barriers to effective management of hypertension in older populations: a narrative review. J Pharm Policy Pract. 2015;8:24. https://doi.org/10.1186/s40545-015-0042-6</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124: 1045–1060. https://doi.org/10.1161/circresaha.118.313236</mixed-citation><mixed-citation xml:lang="en">Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124: 1045–1060. https://doi.org/10.1161/circresaha.118.313236</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. https://doi.org/10.1186/s12916-015-0328-1</mixed-citation><mixed-citation xml:lang="en">Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double- blind, placebo- controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. https://doi.org/10.1186/s12916-015-0328-1</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. SPRINT Research Group. Effect of intensive blood-pressure treatment on patient-r eported outcomes. N Engl J Med. 2017;377:733–744. https://doi.org/10.1056/NEJMoa1611179</mixed-citation><mixed-citation xml:lang="en">Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. SPRINT Research Group. Effect of intensive blood- pressure treatment on patient-r eported outcomes. N Engl J Med. 2017;377:733–744. https://doi.org/10.1056/NEJMoa1611179</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Berlowitz DR, Foy C, Conroy M, Evans GW, Olney CM, Pisoni R, et al. Impact of intensive blood pressure therapy on concern about falling: longitudinal results from the Systolic Blood Pressure Intervention Trial (SPRINT). J Am Geriatr Soc. 2020; 68:614–618. https://doi.org/10.1111/jgs.16264</mixed-citation><mixed-citation xml:lang="en">Berlowitz DR, Foy C, Conroy M, Evans GW, Olney CM, Pisoni R, et al. Impact of intensive blood pressure therapy on concern about falling: longitudinal results from the Systolic Blood Pressure Intervention Trial (SPRINT). J Am Geriatr Soc. 2020; 68:614–618. https://doi.org/10.1111/jgs.16264</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178</mixed-citation><mixed-citation xml:lang="en">McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Postel-Vinay N, Bobrie G, Asmar R, Stephan D, Amar L. Management of arterial hypertension: home blood pressure measurement is a cornerstone for telemonitoring and self-management. Mhealth. 2023;9:18. https://doi.org/10.21037/mhealth-22–51</mixed-citation><mixed-citation xml:lang="en">Postel-Vinay N, Bobrie G, Asmar R, Stephan D, Amar L. Management of arterial hypertension: home blood pressure measurement is a cornerstone for telemonitoring and self-management. Mhealth. 2023;9:18. https://doi.org/10.21037/mhealth-22–51</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte-Silva D, Figueiras A, Herdeiro MT, Teixeira Rodrigues A, Silva Branco F, Polónia J, et al. PERSYVE — design and validation of a questionnaire about adverse effects of antihypertensive drugs. Pharm Pract (Granada). 2014;12(2):396. https://doi.org/10.4321/s1886-36552014000200005</mixed-citation><mixed-citation xml:lang="en">Duarte-Silva D, Figueiras A, Herdeiro MT, Teixeira Rodrigues A, Silva Branco F, Polónia J, et al. PERSYVE — design and validation of a questionnaire about adverse effects of antihypertensive drugs. Pharm Pract (Granada). 2014;12(2):396. https://doi.org/10.4321/s1886-36552014000200005</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
